Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Mechanism of vasopressin-induced platelet aggregation
Thrombosis Research, Volume 45, No. 1, Year 1987
Notification
URL copied to clipboard!
Description
The mechanism of aggregation induced by arginine vasopressin (AVP) was studied in human platelet rich plasma. AVP - over the range of 1.8-113.6 mU/ml - caused a dose-dependent aggregation with a concomitant stimulation of thromboxane B2 (TXB2) formation, d(CH2)5Tyr (Me)AVP did not by itself affect platelet aggregation or TXB2 release, but completely inhibited the action of AVP. DDAVP up to the concentration of 280 pM/ml had no effect on aggregation. Pretreatment of platelets with verapamil, trifluoroperazine or methylimidazole, a thromboxane synthetase blocker, prevented AVP-induced aggregation and TXB2 release. Neither phenidone in lower concentration nor nordihydroguaiaretic acid inhibited the ability of AVP to induce aggregation and TXB2 release. These results are consistent with the hypothesis that human platelets possess AVP receptor of the calcium-dependent vasopressor (V1) subtype and suggest that AVP-induced platelet aggregation is mediated via thromboxane release. © 1987.
Authors & Co-Authors
Rosenkranz, Bernd
Germany, Gerlingen
Robert Bosch Gmbh
Statistics
Citations: 66
Authors: 1
Affiliations: 1
Identifiers
Doi:
10.1016/0049-3848(87)90252-0
ISSN:
00493848